Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Chinese patients with type 2 diabetes and CKD not using RAS inhibitors
ChiCTR2500106051Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Finerenone 10 mg once daily with Placebo once daily (2 arms). Primary endpoint: Change in UACR from baseline (geometric mean ratio to baseline) over 6 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500106051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106051.